Phase 2 N=6 Teduglutide for Enterocutaneous Fistula (ECF)
Postoperative Fistula
Primary: Change in Average 3-day Fistula Percent Volume — 76.33; 441.67 Percent change in fistula volume
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=66 Ice T Postoperative Multimodal Pain Regimen in FPMRS Surgery
Pain, Postoperative · Pelvic Organ Prolapse
Primary: Visual Analog Scores (VAS) — 20; 40 mm
Phase 3 N=360 Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age
Meningococcal Immunisation (Healthy Volunteers)
Primary: Percentage of Participants With Vaccine Seroresponse For Meningococcal Serogroup A, C, Y And W Following Vaccination With MenACYW Conjugate and Menactra® Vaccine…
Phase 2 N=36 Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia
Acute Myeloid Leukemia
Primary: Phase 1: Maximum Tolerated Dose (MTD) of Peg-IFN-α — 180 mcg
N/A N=354 Pharmacological and Non-pharmacological Interventions in Management of Venipuncture Pain.
Child, Hospitalized
Primary: Child Self-reported Pain: Wong-Baker Faces Pain Rating Scale — 2; 2; 2 score on a scale — p=0.511
Phase 2 N=130 COVID-19 PrEP HCW HCQ Study
COVID-19
Primary: Change From Baseline in the Number of Participants With Seroconversion to SARS-CoV-2 at 1 Month — 4; 2 Participants
N/A N=32 Trial of Continuous Versus Cyclic Stimulation in Interstim Therapy
Urge Incontinence
Primary: Number of Micturitions in 24 Hours
Phase 2 N=82 Subcutaneous Methylnaltrexone Versus Placebo for Postoperative Ileus Prevention
Postoperative Ileus
Primary: Time to First Bowel Movement — 61.8; 50.7 hours — p=0.81
N/A N=406 Supporting Asthma Management Behaviors in Aging Adults
Asthma
Primary: Change in Asthma Control Test (ACT) — 15.0; 14.6; 14.3; 16.6 score on a scale
Phase 3 N=240 Clinical Trial of Efficacy and Safety of ММН-407 in Acute Respiratory Viral Infection
Viral Respiratory Infection
Primary: Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms — 4.1; 5.0 days — p=0.0155
Phase 3 N=707 Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers
Meningococcal Immunisation (Healthy Volunteers)
Primary: Percentage of Participants With Antibody Titers >=1:8 Against Meningococcal Serogroup C Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Following…
N/A N=31 Comparison of Motor and Sensory Response With Interstim Stimulation
Overactive Bladder · Urgency-Frequency
Primary: Percent of Symptoms With Improvement of Leaks Reported — 14.4; 19.8; 18.2 Percent change in leaks
N/A N=40 An Adjunctive Family Intervention for Individual Posttraumatic Stress Disorder Treatment
Posttraumatic Neuroses
Primary: Clinician-Administered PTSD Scale, 5th Edition — 18.60; 21.21 score on a scale
N/A N=95 Automatic Self Transcending Meditation Versus Treatment as Usual
Major Depressive Disorder
Primary: Change in Heart Rate Variability (SDNN) From Baseline to End of Study — -0.006; -0.116 S.D. of the normalized N-N interval — p=0.28
Phase 3 N=803 Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine
Infections, Meningococcal
Primary: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement Antibody (rSBA) Titers >=1:8 at 1 Month After Administration of 1 Dose of MenACWY-TT in…